Department of Congenital Heart Diseases and Pediatric Cardiology Silesian Center for Heart Diseases, Maria Curie-Skłodowskiej 9, 41-800 Zabrze, Poland.
Kardiol Pol. 2018;76(8):1257-1262. doi: 10.5603/KP.a2018.0113. Epub 2018 Jun 4.
Atrial septal defect (ASD) type 2, according to current standards, is closed percutaneously usually after the child has reached the age of four to five years. There are limited data regarding such treatment in younger infants.
We sought to evaluate the feasibility, safety, and efficacy of percutaneous ASD closure in children under three years of age.
The research group consisted of 157 children less than three years old with haemodynamically significant ASD, who underwent effective transcatheter ASD closure in a single tertiary centre between 1999 and 2014. The mean procedural age of the treated children was 2.2 years and mean weight was 12.5 kg. In all cases nitinol wire mesh devices were applied (mostly Amplatzer Septal Occluders). ASD was closed using standard technique (except a few cases wherein the left disc of the implant was inserted initially into the right pulmonary vein to prevent oblique position of the device). Procedure-related complications were divided into major and minor ones.
Atrial septal defect was closed in 149 children: 97 with a single ASD and 52 with double/multiple ASD. The procedure was abandoned in eight patients (three with single and five with double/multiple ASD). No death or implant embolisation occurred during the procedure or follow-up, and there was one case of major postprocedural complications. Normalisation of the right ventricular diameter occurred in all patients during one-year follow-up. In the majority of children acceleration of physical development and resolution of accompanying morbidity were observed in follow-up.
Percutaneous ASD closure can be performed safely in children under three years of age with low risk of peri- or postprocedural complications.
根据现行标准,房间隔缺损(ASD)2 型通常在儿童达到 4 至 5 岁后经皮闭合。对于年龄较小的婴儿,此类治疗的相关数据有限。
我们旨在评估在三岁以下儿童中经皮 ASD 闭合的可行性、安全性和疗效。
研究组由 1999 年至 2014 年期间在一家三级中心接受有效经导管 ASD 闭合治疗的 157 名年龄小于三岁、存在血流动力学显著 ASD 的儿童组成。接受治疗的儿童的平均手术年龄为 2.2 岁,平均体重为 12.5 公斤。所有情况下均使用镍钛诺丝网管(主要为 Amplatzer 房间隔封堵器)。采用标准技术闭合 ASD(仅少数情况下,将植入物的左盘片最初插入右肺静脉,以防止器械呈斜位)。将手术相关并发症分为主要并发症和次要并发症。
149 名儿童的 ASD 成功闭合:97 名儿童为单发性 ASD,52 名儿童为多发性 ASD。8 名患者(3 名单发性 ASD 和 5 名多发性 ASD)放弃了手术。在手术或随访过程中,没有死亡或植入物栓塞的情况发生,仅发生 1 例严重的术后并发症。所有患者在 1 年随访期间右心室直径均恢复正常。在大多数儿童中,在随访中观察到体格发育加速和伴随发病率的缓解。
在三岁以下儿童中,经皮 ASD 闭合可以安全进行,围手术期或术后并发症的风险较低。